

FORM PTO-1449			DOCKET NO.:	SERIAL NO.:
INFORMATION DISCLOSURE			701586/50174 DIV	10/060759
STATEMENT			APPLICANT(S): Adam Lerner	
			FILING DATE: Herewith	GROUP NO.: 1614
U.S. PATENT DOCUMENTS				
PS	AA	5,529,914	Hubbell et al.	06/25/1996
PS	AB	5,573,934	Hubbell et al.	11/12/1996
PS	AC	5,601,844	Kagayama et al.	02/11/1997
PS	AD	5,591,776	Cavalla et al.	01/07/1997
PS	AE	5,622,977	Warrelow et al.	04/22/1997
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)				
PS	BA	DEVITA, V.T., ROSENBERG, S.A., HELLMAN, S., "Cancer: Principles & Practice of Oncology." 3rd ed., J. B. Lippincott Company, p. 1843-1847 (1989).		
PS	BB	DANIEL, V. ET AL., "Induction of cytolysis of cultured lymphoma cells by adenosine 3':5'-cyclic monophosphate and isolation of resistant variants." Proc. Natl. Acad. Sci. USA, 70:76 (1973).		
PS	BC	MCCONCEY, D.J. ET AL., "Agents that elevate cAMP stimulate DNA fragmentation in thymocytes." J. Immunol., 145:1227 (1990).		
PS	BD	LOMO, J. ET AL., "TGB-b1 and cyclic AMP promote apoptosis in resting human B lymphocytes." J. Immunol., 154:1634 (1995).		
PS	BE	SCHWABE, U. ET AL., "4-(3-cyclopentyloxy-4-methoxyphenyl)-2pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain." Molecular Pharmacology, 12:900 (1976).		
PS	BF	SHEPPARD, H. ET AL., "Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues." Adv. Cyclic Nucl. Res., 1:103 (1972).		
PS	BG	SILBER, R and STAHL, R., "Chronic lymphocytic leukemia and related diseases." In Hematology 4th ed., W.J. Williams et al. Eds., McGraw-Hill, Inc., p. 1005-1025 (1990).		
PS	BH	BROWN, B.A., "Hematology: Principles and Procedures." 3rd ed. Lea & Febiger, PA, p. 248-250 (1980).		
PS	BI	DALE, D.C. and FEDERMAN, D.D. "The leukemias and the myeloproliferative disorders." Scientific American Medicine 2:16-29 (1996).		
PS	BJ	MENTZ, F. et al. "Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides." British Journal of Haematology 90:957-959 (1995).		
PS	BK	MENTZ, F. et al. "Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells." Blood 88:2172-2182 (1996).		
PS	BL	ZURBONSEN K. et al. "Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the dami cell line." Biochemical Pharmacology 53:1141-1147 (1997).		
PS	BM	WEISS, B. and HAIT, W.N. "Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents." Ann. Rev. Pharmacol. Toxicol. 17:441-477 (1977).		

Phyllis Spivack

10/26/04

FORM PTO-1449		DOCKET NO.:	SERIAL NO.: To be assigned
INFORMATION DISCLOSURE		701586/50174-DIV	
STATEMENT		APPLICANT(S): Adam Lerner	
		FILING DATE: Herewith	GROUP NO.: Unassigned
PS	BN	DREES, M. et al. "3',5'-cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition." Cancer Research 53:3058-3061 (1993).	
PS	BO	JIANG, X. et al. "Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells." Proc. Natl. Acad. Sci. USA 93:11236-11241 (1996).	
PS	BP	ZHU W-H. et al. "Cyclic AMP-specific phosphodiesterase inhibitor rolipam and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism." Life Sci. 63:265-74 (1998).	
NON-PATENT DOCUMENTS			
PS	CA	Zhu et al., <i>Life Sci.</i> , 673(4), 265-274 (1998).	
PS	CB	Kim et al., <i>Blood</i> , 92(7), 2484-2494 (1998) Abstract Only	
EXAMINER:		Phyllis Spivack	DATE: 10/26/04